$14.09
-0.05-0.35%
Ult. Agg.: Oct 26, 7:48 AM
Iovance Biotherapeutics (IOVA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Iovance Biotherapeutics (IOVA) ha pubblicato l'ultima guidance il settembre 29, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $410M - $420M per il periodo.
Rispetto alle previsioni precedenti, Iovance Biotherapeutics ha modificato le sue previsioni di fatturato da un intervallo precedente di .
Iovance Biotherapeutics ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Iovance Biotherapeutics. 13
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.14 | $-0.16 | $-0.19 | $-0.27 |
| Actual | $-0.11 | $-0.19 | $-0.18 | $-0.25 |
| Surprise | +21.4% | -18.8% | +5.26% | +7.41% |
| Revenue | ||||
| Estimate | $87.6M | $76.0M | $78.6M | $71.8M |
| Actual | $99.3M | $71.4M | $86.8M | $67.5M |
| Surprise | +13.4% | -5.96% | +10.3% | -6.08% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.09 | $-0.09 | $-0.11 | $-0.09 |
| Revenue | ||||
| Consensus | $115.5M | $126.7M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.11 | $-0.14 | 21.4 % |
| Q1 | May 7, 2026 | $-0.19 | $-0.16 | -18.8 % |
| Q4 | Feb 24, 2026 | $-0.18 | $-0.19 | 5.26 % |
| Q3 | Nov 6, 2025 | $-0.25 | $-0.27 | 7.41 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $99.31M | $87.60M | 13.4 % |
| Q1 | May 7, 2026 | $71.43M | $75.95M | -5.96 % |
| Q4 | Feb 24, 2026 | $86.77M | $78.64M | 10.3 % |
| Q3 | Nov 6, 2025 | $67.46M | $71.82M | -6.08 % |